Format

Send to

Choose Destination
Nat Rev Cancer. 2017 Jan;17(1):20-37. doi: 10.1038/nrc.2016.108. Epub 2016 Nov 11.

Cancer nanomedicine: progress, challenges and opportunities.

Author information

1
Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
2
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
3
Tarveda Therapeutics, Watertown, Massachusetts 02472, USA.
4
King Abdulaziz University, Jeddah 21589, Saudi Arabia.

Abstract

The intrinsic limits of conventional cancer therapies prompted the development and application of various nanotechnologies for more effective and safer cancer treatment, herein referred to as cancer nanomedicine. Considerable technological success has been achieved in this field, but the main obstacles to nanomedicine becoming a new paradigm in cancer therapy stem from the complexities and heterogeneity of tumour biology, an incomplete understanding of nano-bio interactions and the challenges regarding chemistry, manufacturing and controls required for clinical translation and commercialization. This Review highlights the progress, challenges and opportunities in cancer nanomedicine and discusses novel engineering approaches that capitalize on our growing understanding of tumour biology and nano-bio interactions to develop more effective nanotherapeutics for cancer patients.

PMID:
27834398
PMCID:
PMC5575742
DOI:
10.1038/nrc.2016.108
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center